2025-05-15 - Analysis Report
Okay, here's a draft report summarizing the provided data for Schrodinger Inc. (SDGR). I'll present the numbers first, then add some analysis.

## SDGR (Schrodinger Inc) Stock Analysis Report

**Schrodinger Inc** is a company that develops software for drug discovery and materials science.

### 1. Performance vs. S&P 500 (VOO)

*   Review Stock Ticker: SDGR
*   Company Name: Schrodinger Inc

*   SDGR Cumulative Return: 0.0
*   VOO Cumulative Return: 0.0
*   **Divergence:**
    *   Max: 0.0
    *   Min: 0.0
    *   Current: 0.0
    *   Relative Divergence: 0.0

The relative divergence indicates SDGR's performance relative to its historical range of divergence compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2020-2022  | 0.0% | 0.0% | 0.0   | 1.0 | 1.4   |
| 2021-2023  | 0.0% | 0.0% | 0.0   | 1.0 | 2.6   |
| 2022-2024  | 0.0% | 0.0% | 0.0   | 1.0 | 1.4   |
| 2023-2025  | 0.0% | 0.0% | 0.0   | 1.0 | 1.7   |

**Analysis:**
*   The beta is at 1.0, indicating that SDGR's volatility is the same as the market (S&P 500).
*   The alpha is 0.0, this stock does not outperform the market.

### 2. Recent Stock Price Movement

*   Current Price: 23.76000022888184
*   Last Market Data: `{'price': 23.54, 'previousClose': 23.76, 'change': -0.93}`
*   5-Day Moving Average: 23.888
*   20-Day Moving Average: 25.1542
*   60-Day Moving Average: 22.7651

**Analysis:**

The stock price is currently below both its 5-day and 20-day moving averages, but above its 60-day moving average.  This suggests a recent downward trend but still above longer-term levels. The last market data shows a recent price drop, which could be a short-term fluctuation or the start of a more significant decline.

### 3. Market Risk Indicator (MRI) and Other Indices

*   Market Risk Indicator (MRI): 0.0
*   RSI: 38.128508846121576
*   PPO: -1.3646
*   Recent (20-day) Relative Divergence Change: 0.0 (Negative - short-term decline)
*   Expected Return (%): 0.0

**Analysis:**

*   The MRI is very low, suggesting the stock is Low Risk.
*   The RSI is below 40, indicating that the stock might be approaching oversold conditions.
*   The negative PPO suggests that the price's short-term moving average is below its long-term moving average, signaling a potential downtrend.
*   The negative change in relative divergence aligns with the recent price decline.
*   Given the recent price drop, investors should closely monitor price action and trading volume.

### 4. Recent News & Significant Events

*   \[2025-05-12] - Schrodinger Inc (SDGR) has recently made headlines due to major business developments, regulatory changes, or market events.
*   \[2025-05-15] - Analysts are discussing Schrodinger Inc's (SDGR) recent performance and its outlook in the context of industry trends and global economic factors.
*   \[2025-05-13] - Schrodinger Inc (SDGR)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   \[2025-05-14] - Market experts highlight both risks and opportunities for Schrodinger Inc (SDGR), advising investors to monitor recent news and company announcements.

**Analysis:**

Recent news indicates volatility and attention to SDGR's performance, suggesting careful monitoring is warranted.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-05-07 | -0.82 | 0.06 B$    |
| 2024-11-12 | -0.52 | 0.04 B$    |
| 2024-07-31 | -0.74 | 0.05 B$    |
| 2024-05-01 | -0.76 | 0.04 B$    |
| 2025-05-07 | -0.76 | 0.04 B$    |

**Analysis:**

The company has consistently reported negative EPS values over the past several quarters. While revenue has shown some variability, it has remained relatively stable. This indicates that the company is currently not profitable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2024-12-31   | $0.09B  | 72.61%        |
| 2024-09-30   | $0.04B  | 50.24%        |
| 2024-06-30   | $0.05B  | 66.20%        |
| 2024-03-31   | $0.04B  | 51.61%        |
| 2023-12-31   | $0.07B  | 77.64%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE       |
|--------------|---------|-----------|
| 2024-12-31   | $0.42B  | -9.54%    |
| 2024-09-30   | $0.45B  | -8.49%    |
| 2024-06-30   | $0.47B  | -11.40%   |
| 2024-03-31   | $0.51B  | -10.65%   |
| 2023-12-31   | $0.55B  | -5.59%    |

**Analysis:**

*   Revenue has fluctuated from quarter to quarter, with a recent high in Q4 2024.
*   Profit margins are generally high, indicating the company's ability to control costs, but this does not translate to overall profitability due to other expenses.
*   Equity has been declining, potentially due to continued losses.
*   ROE is negative, reflecting the company's inability to generate profits from its equity.

### 7. Overall Analysis

Based on the data, SDGR presents a mixed picture. The company operates in a potentially high-growth area (drug discovery software), but its financials show consistent losses.

*   **Negatives:**
    *   Negative EPS and ROE highlight profitability concerns.
    *   Recent price declines and negative PPO indicate short-term downward momentum.
    *   High volatility based on recent news could suggest uncertainty.
*   **Positives:**
    *   Relatively high profit margins.
    *   Low MRI suggests low risk.
    *   The RSI is approaching oversold.
    *   Consistent beta is 1.0, same volatility with market

**Conclusion:**

SDGR requires careful monitoring.  Investors should pay close attention to upcoming earnings reports, news events, and any changes in the company's strategic direction. Further research is recommended to understand the underlying reasons for the company's consistent losses and its plans for achieving profitability.
